Home Metabolism P450 (e.g. CYP17) inhibitor Ezutromid

research use only

Ezutromid P450 (e.g. CYP17) inhibitor

Cat.No.S0418

Ezutromid (SMT C1100,BMN 195,VOX-C1100) is a first-in-class, orally active benzoxazole utrophin modulator with an EC50 of 0.91 μM which can be used for the research Duchenne muscular dystrophy (DMD), also inhibits CYP1A2 enzymic activity in human liver microsomes (HLM) with an IC50 of 5.4 μM.
Ezutromid P450 (e.g. CYP17) inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 337.39

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S041801 DMSO]4 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.72%
99.72

Chemical Information, Storage & Stability

Molecular Weight 337.39 Formula

C19H15NO3S

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 945531-77-1 -- Storage of Stock Solutions

Synonyms SMT C1100, BMN 195, VOX-C1100 Smiles CCS(=O)(=O)C1=CC2=C(C=C1)OC(=N2)C3=CC4=CC=CC=C4C=C3

Solubility

In vitro
Batch:

DMSO : 4 mg/mL (11.85 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
CYP1A2 [1]
(in assay of CYP1A2 enzymic activity)
5.4 μM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02858362 Terminated
Duchenne Muscular Dystrophy
Summit Therapeutics
 June 2016 Phase 2
NCT02383511 Completed
Muscular Dystrophy Duchenne
Summit Therapeutics
 February 2015 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map